The use of quantitative proteomics towards biomarker discovery in lung squamous cell carcinoma.
The use of quantitative proteomics towards biomarker discovery in lung squamous cell carcinoma.
复制标题
DOI：
10.3978/j.issn.2218-6751.2013.10.17
复制
发表时间：
2013-12
影响因子：
4
通讯作者：
T. Whitsett;L. Inge;N. Tran
中科院分区：
文献类型：
--
作者：
T. Whitsett;L. Inge;N. Tran
由于晚期发现的肿瘤占优势，晚期肺癌的高死亡率要求发现和临床验证用于诊断早期疾病的生物标志物。定量蛋白质组学技术能够鉴定具有诊断、预后和预测价值的蛋白质生物标志物。最近的工作已经证明了在正常、癌前和癌性病变中使用定量蛋白质组学对发现早期肺癌的生物标志物以及发现肺癌发生的新机制的实用性。
The high mortality rate in advanced lung cancer, due to a preponderance of tumors discovered at advanced stage, demands the discovery and clinical validation of biomarkers for diagnosing early stage disease. Quantitative proteomics technologies are capable of identifying protein biomarkers with diagnostic, prognostic, and predictive value. Recent works have demonstrated the utility in using quantitative proteomics across normal, pre-cancerous, and cancerous lesions towards the discovery of biomarkers for early stage lung cancer, as well as discovering novel mechanisms of lung carcinogenesis.